Is CNC a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Medicaid scale and margin recovery, with revenue (ttm) at ~$180B. The bear case rests on centene withdrew its 2025 guidance and its stock fell roughly 40% in a single day in July 2025 after actuaries flagged that its ACA Marketplace assumptions were too aggressive, so guidance credibility and forecasting accuracy remain live concerns even after two strong 2026 quarters. Analysts covering it are spread from $56.00 to $85.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Centene withdrew its 2025 guidance and its stock fell roughly 40% in a single day in July 2025 after actuaries flagged that its ACA Marketplace assumptions were too aggressive, so guidance credibility and forecasting accuracy remain live concerns even after two strong 2026 quarters. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $56.00, -19.0% from the $69.16 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Medicaid scale and margin recovery. Centene is the largest Medicaid managed-care organization in the US, with about 12.5 million members across roughly 30 states. The most optimistic analyst target on CNC is $85.00, +22.9% from the $69.16 price. That figure is only reachable if this thesis works close to its best case.

Centene withdrew its 2025 guidance and its stock fell roughly 40% in a single day in July 2025 after actuaries flagged that its ACA Marketplace assumptions were too aggressive, so guidance credibility and forecasting accuracy remain live concerns even after two strong 2026 quarters. The stock has nearly doubled over the past year, so expectations are now higher than they were. Consensus for Q3 2026 is only about $0.10 of EPS and for Q4 a loss of about $1.09, so the second half carries little margin for cost surprises. Medicaid is the single largest source of revenue, and federal legislation enacted in 2025 is projected to cut a large amount of Medicaid funding over the coming years, which could reduce enrollment and pressure rates. Medical cost trends in behavioral health, home health, and high-cost drugs have run hotter than expected, and results are sensitive to state rate negotiations, redeterminations, ACA subsidy policy and the outcome of the November 2026 midterm elections. On a trailing basis the company still shows a net loss of about $5.1 billion because of the 2025 charges. The most pessimistic published target is $56.00, -19.0% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Centene Corporation operates as a managed care company that provides programs and services to under-insured families, and commercial organizations in the United States.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Medicaid scale and margin recovery) stalling in the reported numbers rather than in the narrative, the risk above (centene withdrew its 2025 guidance and its stock fell roughly 40% in a single day in July 2025 after actuaries flagged that its ACA Marketplace assumptions were too aggressive, so guidance credibility and forecasting accuracy remain live concerns even after two strong 2026 quarters) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

Centene is a managed-care organization that administers government-sponsored and subsidized health insurance. It is the largest Medicaid managed-care company in the US, the top carrier on the ACA Marketplace, and also runs Medicare Advantage and prescription-drug plans.

In mid-2025 Centene withdrew its full-year guidance after an independent actuarial review found its ACA Marketplace morbidity and risk-adjustment assumptions were too optimistic. The stock fell roughly 40% in a single session and hit multi-year lows, and Wall Street issued downgrades. The company went on to report a net loss of about $6.7 billion for 2025.

Centene reported total revenue of about $194.8 billion in 2025, up roughly 19% year over year, and about $180 billion over the twelve months to June 2026. Analysts expect roughly $196 billion for full-year 2026. Health insurance is a thin-margin business, so profits are far smaller than that top line.